Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Saved in:
Bibliographic Details
Title: Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.
Authors: Ahrens M; Goethe University Frankfurt, University Hospital, Department of Hematology and Medical Oncology, Frankfurt, Germany. Electronic address: m.ahrens@med.uni-frankfurt.de., Haanen J; Goethe University Frankfurt, University Hospital, Department of Hematology and Medical Oncology, Frankfurt, Germany; Netherlands Cancer Institute, Amsterdam and Leiden University Medical Center, Leiden, Netherlands and Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Albiges L; Institut Gustave Roussy, Paris, France., Goupil MG; Hopital Saint André, Département d'Oncologie, Bordeaux, France., Boleti E; Royal Free London NHS Foundation Trust, London, UK., Gravis G; Department of Medical Oncology, Institut Paoli-Calmettes, Aix Marseille Univ, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France., Fléchon A; Centre Léon Bérard, Lyon, France., Grimm MO; Department of Urology, Jena University Hospital, Friedrich-Schiller University and Comprehensive Cancer Center Germany (CCCG), Jena, Germany., Bedke J; Clinic for Urology, University Hospital, Tuebingen, Germany and Dept. of Urology & Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany., Barthélémy P; Hôpitaux Universitaires de Strasbourg, Strasbourg, France., Castellano D; Clinic of Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Mellado B; Clinic for Oncology, Hospital Clinic de Barcelona, Spain., Ivanyi P; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Claudia von Schelling Comprehensive Cancer Center, Hannover, Germany., Rottey S; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium., Flörcken A; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany., Suárez C; Medical Oncology, Vall d'Hebron Institut of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Maroto JP; San Pau Hospital, (Hospital de la Santa Creu i Sant Pau), Barcelona, Spain., Grünwald V; Clinic for Urology and Clinic for Medical Oncology, University Hospital, Essen, Germany., Oosting S; University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Kopecky J; Faculty Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Zschäbitz S; University Hospital, NCT Heidelberg, Heidelberg, Germany., Boegemann M; University Hospital Münster, Clinic for Urology, Münster, Germany., Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic., Niegisch G; Department of Urology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, and Centre for Integrated Oncology (CIO) Düsseldorf, CIO ABCD (Aachen-Bonn-Cologne-Düsseldorf), Düsseldorf, Germany., Goebell PJ; Erlangen University Hospital, Department of Urology and Pediatric Urology, Erlangen, Germany., Waddell T; The Christie NHS Foundation Trust, Manchester, UK., Joly F; Centre Régional de Lutte contre le Cancer François Baclesse, Caen, France., Priou F; Hospital Center Departmental De Vendée, La-Roche-sur-Yon, France., Retz M; Technical University of Munich, School of Medicine and Health, Department of Urology, TUM University Hospital, Munich, Germany., Siemer S; Department of Urology, Saarland University, Homburg/Saar, Germany., Zimmermann U; University Medical Center Greifswald, Clinic for Urology, Greifswald, Germany., Deckbar D; Goethe University Frankfurt, University Hospital, Department of Hematology and Medical Oncology, Frankfurt, Germany., Burkholder I; Department of Health Sciences, Fulda University of Applied Sciences, Fulda, Germany., Stöhr C; Institute of Pathology University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Hartmann A; Institute of Pathology University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center Erlangen EMN (CCC ER-ERM), Erlangen, Germany., Bergmann L; Goethe University Frankfurt, University Hospital, Department of Hematology and Medical Oncology, Frankfurt, Germany.
Corporate Authors: Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN)
Source: Cancer treatment and research communications [Cancer Treat Res Commun] 2026 Jul 18; Vol. 48, pp. 101319. Date of Electronic Publication: 2026 Jul 18.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101694651 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-2942 (Electronic) Linking ISSN: 24682942 NLM ISO Abbreviation: Cancer Treat Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2468-2942
DOI:10.1016/j.ctarc.2026.101319